Efficacy of Carminal in Helicobacter Pylori Gastritis

Not Applicable

Recruiting

• Conditions: H Pylori Gastritis; H Pylori Infection; H Pylori Eradication; Gastritis Associated With Helicobacter Pylori; Gastric Mucosal Lesion

• Registration Number: NCT07179237
• Lead Sponsor: Catalysis SL

Brief Summary

Eighty patients will be included and randomized in two groups, one group (40 patients) will be administered 30 ml of the supplement Carminal, once a day, plus therapy for HP gastitis and the control group (40 patients) will be given standard therapy for HP gastritis with placebo. Treatment will begin after complection of upper endoscopy with histology results from biopted gastric mucosa. Treatment with Carminal will be continued after successful HP eradication during 12 weeks. The final evaluation will take place 12 weeks after the last Carminal intake, when control endoscopy with histology will be performed. The study will last approximately 24 weeks.

Detailed Description

Helicobacter pylori-induced gastritis is an infectious disease based on objective pathological criteria. After the successful eradication of the infection, the recovery of the mucosa occurs through a gradual process that lasts several months. HP eradication is a therapeutic modality for the treatment of non-atrophic gastritis, and it leads to the regression of atrophic gastritis and the reduction of the risk of gastric cancer. In patients with histologically verified intestinal metaplasia, HP eradication does not reduce the risk of malignancy, but reduces inflammation and atrophy, thereby slowing its further progression. It is considered that advanced changes of the mucosa are not fully reversible, while even atrophy can be reversible in certain cases. There are controversial data about reversibility of intestinal metaplasia. However, HP treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. On the other hand, the role of HP and antibiotic therapies and their impact on the gut microbiota are also considered.

The Aloe vera plant (Aloe vera) is a well-known natural substance with several advantages. Aloe vera is frequently utilized as a fundamental component in medications and cosmetics, either directly or after being processed with additional substances. Aloe vera is a member of the Liliaceae family, which has over 200 species. Multiple preclinical studies have demonstrated that ingesting aloe vera juice in specific amounts may contribute to healing stomach ulcers and may be a natural cure for heartburn. Additionally, according to experimental studies aloe vera has the capacity to increase the production of pepsin, a stomach enzyme that aids in digestion. These findings suggest that using a combination of aloe vera with additional substances can have a synergistic antinflammatory and immunomodulatory effect in vivo on gastric mucosa and peptic ulcer disease on animal models.

Carminal, produced by Laboratorios Catalysis, S. L., is an oral solution and supplement that combines aloe vera extract and various substances known for their potential antioxidant, anti-inflammatory and immunomodulatory properties on gastric mucosa.

The goal of this study is to assess how Carminal affects the HP eradication and recovery of gastric mucosa after successful HP eradication and effect on related symptoms.

The trial will be conducted in accordance with the protocol, Good Clinical Practice (GCP) and in compliance with the regulations in force in the Republic of Serbia.

Study Timeline

• Study Start: 2025-08-04
• Status Verified: 2025-09
• Study First Submitted: 2025-09-09
• Study First Submitted QC: 2025-09-16
• Last Update Submitted: 2025-09-16
• Study First Posted: 2025-09-17
• Last Update Posted: 2025-09-17
• Primary Completion: 2026-08-03
• Study Completion: 2026-10-05

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Patients aged 18 years or older
• Patients with clinical symptoms of dyspepsia
• Patients diagnosed with Helicobacter pylori positive gastritis, confirmed by upper endoscopy with histology
• Patients who give written informed consent to participate in the study

Exclusion Criteria

• Patients with peptic ulcer disease
• Patients with previous gastric surgery
• Patients with current malignancy or the history of any previous malignancies
• Patients taking another investigational product, or have taken any investigational product in the last year
• Patients with known hypersensitivity to any ingredients found in the investigational product.
• Decompensated intercurrent illnesses, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver disease, and psychiatric illnesses that may limit adherence to the requirements of the clinical trial, or any other special condition that, according to the physician's judgement, jeopardises the patient's health or life during participation in the trial.
• Planned pregnancy for the duration of trial, pregnancy, breast feeding, or postpartum period.
• Patients with human immunodeficiency virus (HIV).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Glasgow Dyspepsia Severity Score	Baseline, Week 7 (post-eradication), Week 20 (end of treatment)	Change in dyspeptic symptoms assessed using the Glasgow Dyspepsia Severity Score questionnaire at baseline, after eradication therapy, and at the end of Carminal/placebo treatment.
Endoscopic assessment of gastric mucosa	Baseline and Week 21	Endoscopic evaluation of gastric mucosa performed before treatment and at the end of the study to assess mucosal recovery, including presence of gastritis, intestinal metaplasia, and other morphological changes.
Histological assessment of gastric mucosa	Baseline and Week 21	Histological analysis of gastric biopsies to evaluate inflammation, atrophy, foveolar hyperplasia, and intestinal metaplasia before and after treatment.

Secondary Outcome Measures

Name	Time	Method
Leeds Dyspepsia Score	Baseline, Week 7, Week 20	Change in dyspeptic symptoms assessed using the Leeds Dyspepsia Score questionnaire at baseline, after eradication therapy, and at the end of treatment.
Helicobacter pylori status (HP antigen stool test)	Week 7	HP antigen presence in stool samples to confirm eradication success after 14-day standard therapy.
Patient satisfaction after treatment completion	Week 20	Patient-reported satisfaction with treatment outcomes collected via questionnaire at the end of the study.
Occurrence of adverse events	Throughout the study (Week 1 to Week 21)	Monitoring and recording of any adverse events (AEs), including type, duration, intensity, seriousness, and outcome.

Trial Locations

Locations (2)

Clinical Center of Serbia - Clinic for Gastroenterohepatology; 🇷🇸 Belgrade, Central Serbia, Serbia

Zvezdara Medical Center - Department of Gastroenterology; 🇷🇸 Belgrade, Central Serbia, Serbia